PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9726815-4 1998 Phenobarbital treatment increased the number of CYP2A5-positive centrilobular hepatocytes and the CYP2A5-positive areas were extended into the middle zone in all strains, but periportal hepatocytes remained negative. Phenobarbital 0-13 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 48-54 11162586-4 2001 Phenobarbital (PB) elicited a 3-fold increase in CYP2A5 expression (catalytic activity and mRNA), while the cAMP and protein kinase A (PKA) stimulators dibutyryl-cAMP, forskolin and Sp-cAMPs caused up to 18-fold increases in the amount of CYP2A5 mRNA. Phenobarbital 0-13 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 49-55 11162586-4 2001 Phenobarbital (PB) elicited a 3-fold increase in CYP2A5 expression (catalytic activity and mRNA), while the cAMP and protein kinase A (PKA) stimulators dibutyryl-cAMP, forskolin and Sp-cAMPs caused up to 18-fold increases in the amount of CYP2A5 mRNA. Phenobarbital 0-13 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 239-245 11162586-4 2001 Phenobarbital (PB) elicited a 3-fold increase in CYP2A5 expression (catalytic activity and mRNA), while the cAMP and protein kinase A (PKA) stimulators dibutyryl-cAMP, forskolin and Sp-cAMPs caused up to 18-fold increases in the amount of CYP2A5 mRNA. Phenobarbital 15-17 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 49-55 11162586-4 2001 Phenobarbital (PB) elicited a 3-fold increase in CYP2A5 expression (catalytic activity and mRNA), while the cAMP and protein kinase A (PKA) stimulators dibutyryl-cAMP, forskolin and Sp-cAMPs caused up to 18-fold increases in the amount of CYP2A5 mRNA. Phenobarbital 15-17 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 239-245 10447669-0 1999 Modulation of murine phenobarbital-inducible CYP2A5, CYP2B10 and CYP1A enzymes by inhibitors of protein kinases and phosphatases. Phenobarbital 21-34 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 45-51 10447669-2 1999 In this study, the involvement of several protein kinase and phosphatase pathways on constitutive and phenobarbital-induced activities of CYP2A5, CYP2B10 and CYP1A1/2 in primary mouse hepatocytes was determined using well-defined chemical modulators of intracellular protein phosphorylation and desphosphorylation events. Phenobarbital 102-115 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 138-144 10447669-3 1999 A 48-h treatment of the hepatocytes with 2-aminopurine, a nonspecific serine/threonine kinase inhibitor, elicited dose-dependent increases in both basal and phenobarbital-induced CYP2A5 catalytic activity (assayed as coumarin 7-hydroxylation), the maximal induction being 60-fold greater than the control value upon cotreatment with 1.5 mM phenobarbital and 10 mM 2-aminopurine. Phenobarbital 157-170 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 179-185 10447669-3 1999 A 48-h treatment of the hepatocytes with 2-aminopurine, a nonspecific serine/threonine kinase inhibitor, elicited dose-dependent increases in both basal and phenobarbital-induced CYP2A5 catalytic activity (assayed as coumarin 7-hydroxylation), the maximal induction being 60-fold greater than the control value upon cotreatment with 1.5 mM phenobarbital and 10 mM 2-aminopurine. Phenobarbital 340-353 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 179-185 10447669-7 1999 The serine/threonine phosphatase inhibitors tautomycin, calyculin A and okadaic acid all reduced both basal and phenobarbital-induced CYP2A5, CYP2B10 and CYP1A1/2 activities. Phenobarbital 112-125 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 134-140 9726815-4 1998 Phenobarbital treatment increased the number of CYP2A5-positive centrilobular hepatocytes and the CYP2A5-positive areas were extended into the middle zone in all strains, but periportal hepatocytes remained negative. Phenobarbital 0-13 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 98-104 9726815-5 1998 Fifty percent of the spontaneous foci in untreated mice, over 90% of the foci in mice treated with NDEA or phenobarbital and all of the hepatocellular adenomas and carcinomas displayed positive immunostaining and a strong CYP2A5 mRNA signal by in situ hybridization. Phenobarbital 107-120 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 222-228 1520280-1 1992 Pyrazole, cobalt and phenobarbital increase the activity of coumarin 7-hydroxylase (COH) in mouse liver. Phenobarbital 21-34 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 60-82 9007836-4 1997 Phenobarbital increased hepatic CYP 2 A 5-mediated coumarin 7-hydroxylase (COH) activity (13.2-fold) and the amount of CYP 2 A 5 steady-state mRNA (10.6-fold). Phenobarbital 0-13 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 32-41 9007836-4 1997 Phenobarbital increased hepatic CYP 2 A 5-mediated coumarin 7-hydroxylase (COH) activity (13.2-fold) and the amount of CYP 2 A 5 steady-state mRNA (10.6-fold). Phenobarbital 0-13 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 51-73 9007836-4 1997 Phenobarbital increased hepatic CYP 2 A 5-mediated coumarin 7-hydroxylase (COH) activity (13.2-fold) and the amount of CYP 2 A 5 steady-state mRNA (10.6-fold). Phenobarbital 0-13 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 119-128 7528014-3 1994 The constitutive activity and inducibility of COH was totally blocked by treatment of hepatocytes with actinomycin D, and short initial treatment with cycloheximide caused superinducibility when co-administered with PB. Phenobarbital 216-218 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 46-49 7528014-5 1994 Administration of dibutyryl cAMP, forskolin, and 3-isobutyl-1-methylxanthine (IBMX) enhanced both basal and PB-induced COH activities and CYP2A5 mRNA levels, indicating that cAMP plays a major role in CYP2A5 expression. Phenobarbital 108-110 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 119-122 7528014-5 1994 Administration of dibutyryl cAMP, forskolin, and 3-isobutyl-1-methylxanthine (IBMX) enhanced both basal and PB-induced COH activities and CYP2A5 mRNA levels, indicating that cAMP plays a major role in CYP2A5 expression. Phenobarbital 108-110 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 138-144 7528014-5 1994 Administration of dibutyryl cAMP, forskolin, and 3-isobutyl-1-methylxanthine (IBMX) enhanced both basal and PB-induced COH activities and CYP2A5 mRNA levels, indicating that cAMP plays a major role in CYP2A5 expression. Phenobarbital 108-110 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 201-207 7528014-2 1994 CYP2A5-mediated coumarin 7-hydroxylase (COH) activity was retained in simple culture conditions for at least 96 hours and the activity was inducible up to 33-fold by phenobarbital (PB). Phenobarbital 166-179 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 0-6 7528014-2 1994 CYP2A5-mediated coumarin 7-hydroxylase (COH) activity was retained in simple culture conditions for at least 96 hours and the activity was inducible up to 33-fold by phenobarbital (PB). Phenobarbital 166-179 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 16-38 7528014-2 1994 CYP2A5-mediated coumarin 7-hydroxylase (COH) activity was retained in simple culture conditions for at least 96 hours and the activity was inducible up to 33-fold by phenobarbital (PB). Phenobarbital 166-179 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 40-43 7528014-2 1994 CYP2A5-mediated coumarin 7-hydroxylase (COH) activity was retained in simple culture conditions for at least 96 hours and the activity was inducible up to 33-fold by phenobarbital (PB). Phenobarbital 181-183 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 0-6 7528014-2 1994 CYP2A5-mediated coumarin 7-hydroxylase (COH) activity was retained in simple culture conditions for at least 96 hours and the activity was inducible up to 33-fold by phenobarbital (PB). Phenobarbital 181-183 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 16-38 7528014-2 1994 CYP2A5-mediated coumarin 7-hydroxylase (COH) activity was retained in simple culture conditions for at least 96 hours and the activity was inducible up to 33-fold by phenobarbital (PB). Phenobarbital 181-183 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 40-43 8069948-2 1994 CYP2A5 antibody inhibited AFB1 and NDEA metabolism by 40-60% in untreated hamsters and after treatment with phenobarbital (PB) or 3-methylcholanthrene (MC). Phenobarbital 108-121 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 0-6 8069948-2 1994 CYP2A5 antibody inhibited AFB1 and NDEA metabolism by 40-60% in untreated hamsters and after treatment with phenobarbital (PB) or 3-methylcholanthrene (MC). Phenobarbital 123-125 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 0-6 1520280-1 1992 Pyrazole, cobalt and phenobarbital increase the activity of coumarin 7-hydroxylase (COH) in mouse liver. Phenobarbital 21-34 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 84-87 1868078-1 1991 The induction mechanism by pyrazole or phenobarbital of coumarin 7-hydroxylase (cytochrome P450coh) was investigated in DBA/2J male mice. Phenobarbital 39-52 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 56-78 28298240-10 2017 Inductions of Cyp2a5 activity by PYR and PB were accompanied by increases of Cyp2a4/5 mRNA. Phenobarbital 41-43 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 14-20 34880749-6 2021 Moreover, treatment of mice with phenobarbital, a known inducer of both CAR and Cyp2a5, increases expression of Cyp2a5 suggesting a potential relationship between CAR and Cyp2a5 expression. Phenobarbital 33-46 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 80-86 34880749-6 2021 Moreover, treatment of mice with phenobarbital, a known inducer of both CAR and Cyp2a5, increases expression of Cyp2a5 suggesting a potential relationship between CAR and Cyp2a5 expression. Phenobarbital 33-46 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 112-118 34880749-6 2021 Moreover, treatment of mice with phenobarbital, a known inducer of both CAR and Cyp2a5, increases expression of Cyp2a5 suggesting a potential relationship between CAR and Cyp2a5 expression. Phenobarbital 33-46 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 171-177 2573050-2 1989 SKF-525A, an inhibitor of phenobarbital-inducible monooxygenase activities has a much weaker effect on COH than the other three drugs, even though COH is a phenobarbital-inducible enzyme. Phenobarbital 156-169 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 147-150 2712571-6 1989 The inducibility of coumarin 7-hydroxylase by phenobarbital (PB) and its genetic regulation have been previously studied by A. W. Wood and colleagues ((1974) Science 185, 612-614; (1979); J. Biol. Phenobarbital 46-59 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 20-42 2712571-6 1989 The inducibility of coumarin 7-hydroxylase by phenobarbital (PB) and its genetic regulation have been previously studied by A. W. Wood and colleagues ((1974) Science 185, 612-614; (1979); J. Biol. Phenobarbital 61-63 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 20-42 2712571-12 1989 Immunoinhibition of microsomal coumarin 7-hydroxylase is practically 100% for control animals and after pretreatment with pyrazole or PB. Phenobarbital 134-136 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 31-53 2903743-10 1988 In immunoblot experiments with anti-P-450Coh antibody, the amount of P-450Coh was considerably higher in DBA/2N mice treated with phenobarbital, TCPOBOP, or pyrazole in comparison with the AKR/J mice, indicating a strain specificity in the inducibility of coumarin 7-hydroxylase by pyrazole. Phenobarbital 130-143 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 256-278 6436023-1 1984 Phenobarbital-induced coumarin 7-hydroxylase is high in DBA/2J and low in C57BL/6N inbred mice; this genetic difference is encoded by the Coh locus on chromosome 7. Phenobarbital 0-13 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 22-44 6436023-3 1984 P-450 fractions, highly specific for phenobarbital-inducible coumarin 7-hydroxylase activity, were purified from DBA/2J and C57BL/6N mouse liver microsomes. Phenobarbital 37-50 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 61-83 4043084-4 1985 This increase was much higher than that caused by phenobarbital, the only well known inducer of coumarin 7-hydroxylase. Phenobarbital 50-63 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 96-118 32503880-7 2020 Cyp1a2, Cyp2a5, Cyp2c29, and Cyp2e1 gene expression levels under physiological conditions and Cyp1a2, Cyp2a5, and Cyp2b10 gene expression levels under phenobarbital-treated conditions were lower in Nrf2-/- mice compared to WT mice. Phenobarbital 151-164 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 102-108 24494203-5 2014 Nrf2(-/-) mice showed attenuated Cyp2b10 and Cyp2a5 induction by phenobarbital, a classical Cyp2b inducer. Phenobarbital 65-78 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 45-51 22859313-9 2012 Phenobarbital, dibutyryl-cAMP, and peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) overexpression stimulate heme biosynthesis and induce CYP2A5. Phenobarbital 0-13 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 170-176 14566026-6 2003 The hepatic CYP2A5 inducers pyrazole and phenobarbital neither changed the CYP2A5 expression pattern nor damaged the olfactory mucosa. Phenobarbital 41-54 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 12-18 14566026-6 2003 The hepatic CYP2A5 inducers pyrazole and phenobarbital neither changed the CYP2A5 expression pattern nor damaged the olfactory mucosa. Phenobarbital 41-54 cytochrome P450, family 2, subfamily a, polypeptide 5 Mus musculus 75-81